However, FUNDC1 worsened relapse-free survival in bladder cancer (RFS: HR = 2.15, 95% CI from 1.01 to 4.58, logrank P = 0.043) (Figures 3E,F). This evidence concerns the gene FUNDC1 and urinary bladder cancer.